Semiparametric efficient estimation of survival distributions in two-stage randomisation designs in clinical trials with censored data

DOI10.1093/biomet/93.1.163zbMath1152.62397OpenAlexW2086498948WikidataQ57446547 ScholiaQ57446547MaRDI QIDQ5503384

Anastasios A. Tsiatis, Abdus S. Wahed

Publication date: 15 January 2009

Published in: Biometrika (Search for Journal in Brave)

Full work available at URL: https://doi.org/10.1093/biomet/93.1.163

zbMATH Keywords

tables influence function censoring two-stage design weighted estimator inverse probability potential outcome regular asymptotically linear estimator

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10) Nonparametric estimation (62G05) Censored data models (62N01) Estimation in survival analysis and censored data (62N02) General considerations in statistical decision theory (62C05)

Related Items (11)

Sensitivity analysis for subsequent treatments in confirmatory oncology clinical trials: A two‐stage stochastic dynamic treatment regime approach ⋮ Semiparametric estimation of treatment effect with time-lagged response in the presence of informative censoring ⋮ Flexible inference of optimal individualized treatment strategy in covariate adjusted randomization with multiple covariates ⋮ Comparison of treatment regimes with adjustment for auxiliary variables ⋮ Q-learning with censored data ⋮ Evaluation of Viable Dynamic Treatment Regimes in a Sequentially Randomized Trial of Advanced Prostate Cancer ⋮ Performance guarantees for individualized treatment rules ⋮ Comparing treatment policies with assistance from the structural nested mean model ⋮ Estimation of survival quantiles in two-stage randomization designs ⋮ Pattern-mixture-type estimation and testing of neuroblastoma treatment regimes ⋮ Inference for non-regular parameters in optimal dynamic treatment regimes

This page was built for publication: Semiparametric efficient estimation of survival distributions in two-stage randomisation designs in clinical trials with censored data